Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DNI5M0
|
|||
| Drug Name |
XNW4107
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Bacterial infection [ICD-11: 1A00-1C4Z; ICD-10: A00-B99] | Phase 1 | [1] | |
| Company |
Sinovent
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Staphylococcus Beta-lactamase (Stap-coc blaZ) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04802863) A Phase 1, Open-label Study to Evaluate the Safety and Intrapulmonary Pharmacokinetics of XNW4107, Imipenem and Cilastatin in Healthy Subjects. U.S.National Institutes of Health. | |||
| REF 2 | In vitro and in vivo activities of a novel beta-lactamase inhibitor combination imipenem/XNW4107 against recent clinical Gram-negative bacilli from China. J Glob Antimicrob Resist. 2022 Dec;31:1-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.